Plasminogen activator expression in human atherosclerotic lesions

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 9, 1995, Pages 1444-1455

  Lupu, Florea ^a,b   Heim, Dominik A ^b   Bachmann, Fedor ^a,b   Hurni, Michel ^b   Kakkar, V V ^a   Kruithof, Egbert K O ^b  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

atherosclerosis; macrophages; smooth muscle cells; tissue type plasminogen activator; urokinase type plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; EXTRACELLULAR MATRIX; FIBRIN DEPOSITION; HUMAN; HUMAN TISSUE; MACROPHAGE; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0029112387     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.15.9.1444     Document Type: Article

References (38)

1. Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen R, Arnout J, eds. Thrombosis and Haemostasis. Leuven, Belgium: Leuven University Press; 1987:227-265.
2. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol. 1989;109:309-315.
3. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol. 1990;110: 767-775.
4. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol. 1990;110:1361-1367.
5. Hamsten A, Walldius G, Szamosi A, Blomback M, De Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction, Lancet. 1987;2:3-9.
6. Rocha E, Alfaro MJ, Páramo JA, Canadell JM. Preoperative identification of patients at high risk of deep venous thrombosis despite prophylaxis in total hip replacement. Thromb Haemost. 1988;59: 93-95.
7. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
8. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
9. Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990;67:61-67.
10. Bini A, Fenoglio JJ Jr, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis: use of monoclonal antibodies. Arteriosclerosis. 1989;9:109-121.
11. Holland P. Localization of gene transcripts in embryo sections: in situ hybridization with RNA probes. In: Hogan B, Constantini F, Lacey E, eds. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1986:228-244.
12. van Noorden CJF, Frederiks WM. Enzyme Histochemistry: A Laboratory Manual of Current Methods. Oxford, UK: Oxford Scientific Publishers; 1992:90-91.
13. Bigbee WL, Weintraub HB, Jensen RH. Sensitive fluorescence assays for urokinase using synthetic peptide 4-methoxy-beta-naphthylamide substrates. Anal Biochem. 1978;88:114-122.
14. Todd AS. The histological localization of fibrinolysin activator. J Pathol Bacteriol. 1959;78:281-290.
15. Padro T, Quax PHA, Van den Hoogen CM, Roholl P, Verheijen JH, Emeis JJ. Tissue-type plasminogen activator and its inhibitor in rat aorta: effect of endotoxin. Arterioscler Thromb. 1994;14: 1459-1465.
16. Barnathan ES, Kuo A, Rosenfeld L, Karikó K, Leski M, Robbiati F, Nolli ML, Henkin J, Cines DB. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem. 1990;265:2865-2872.
17. Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res. 1980;18:815-830.
18. Emeis JJ. Mechanisms involved in short-term changes in blood levels of tissue-type plasminogen activator. In: Kluft C, ed. Tissue-Type Plasminogen Activator: Physiological and Clinical Aspects. Boca Raton, Fla: CRC Press; 1988:21-35.
19. Giles AR, Nesheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost. 1990;63:476-481.
20. Underwood MJ, de Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res. 1993;27:882-885.
21. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993; 13:1218-1226.
22. Vassalli J-D, Wohlwend A, Belin D. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. Curr Top Microbiol Immunol. 1992;181:65-86.
23. Hart PH, Vitti GF, Burgess DR, Singleton DK, Hamilton JA. Human monocytes can produce tissue-type plasminogen activator. J Exp Med. 1989;169:1509-1514.
24. Falk E. Why do plaques rupture? Circulation. 1992;86(suppl III): III-30-III-42.
25. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
26. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941-944.
27. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulation of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131-138.
28. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
29. Ellis V, Danø K. Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost. 1991;17:194-200.
30. Ellis V, Behrendt N, Danø K. Cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis. Methods Enzymol. 1993;223:223-233.
31. Danø K, Behrendt N, Brunner N, Ellis V, Plough M, Pyke C. The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 1994;8(suppl 1):189-203.
32. Welgus HG, Fliszar CJ, Seltzer JL, Schmid TM, Jeffrey JJ. Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72-kDa type IV collagenase. J Biol Chem. 1990;265:13521-13527.
33. Chin JR, Murphy G, Werb Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase: biosynthesis, isolation, characterization, and substrates. J Biol Chem. 1985;260: 12367-12376.
34. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of Stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991;88:8154-8158.
35. Galis GS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
36. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Circulation. 1990;82(suppl II):II-47-II-59.
37. Lendon CL, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis. 1991;87:87-90.
38. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 1991;266: 9419-9427.